|
|
|
Insider
Information: |
Machado Clarence Patrick |
Relationship: |
Director |
City: |
San Francisco |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
11 |
|
Direct
Shares |
175,082 |
|
Indirect Shares
|
185,606,208 |
|
|
Direct
Value |
$1,141,143 |
|
|
Indirect Value
|
$1,576,420,213 |
|
|
Total
Shares |
185,781,290 |
|
|
Total
Value |
$1,577,561,355 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
2
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
2
|
0
|
|
|
|
Gain/Loss Ratio : |
-2.0
|
0.0
|
Percentage
Gain/Loss : |
-80.8%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Medivation Inc |
MDVN |
Director |
2016-09-28 |
0 |
2012-02-08 |
0 |
Premium* |
|
Endocyte Inc |
ECYT |
Director |
2018-12-21 |
0 |
2018-02-27 |
0 |
Premium* |
|
Chimerix Inc |
CMRX |
Director |
2015-12-29 |
10,000 |
2015-12-29 |
0 |
Premium* |
|
Scynexis Inc |
SCYX |
Director |
2016-09-15 |
60,000 |
2016-06-24 |
0 |
Premium* |
|
Sio Gene Therapies Inc |
SIOX |
10% Owner |
|
0 |
2019-03-18 |
105,952,381 |
Premium* |
|
Tekmira Pharmaceuticals Corp |
TKMR |
10% Owner |
|
0 |
2016-10-18 |
16,013,540 |
Premium* |
|
Myovant Sciences Ltd. |
MYOV |
10% Owner |
|
0 |
2019-06-04 |
40,765,599 |
Premium* |
|
Adverum Biotechnologies, Inc |
ADVM |
Director |
2021-03-24 |
88,182 |
2017-03-14 |
0 |
Premium* |
|
Urovant Sciences Ltd. |
UROV |
10% Owner |
2018-10-01 |
0 |
2019-06-19 |
22,860,013 |
Premium* |
|
Arcus Biosciences Inc |
RCUS |
Director |
2023-06-15 |
16,900 |
2020-06-04 |
0 |
Premium* |
|
Acelyrin, Inc. |
SLRN |
Director |
2023-10-04 |
0 |
2023-10-04 |
14,675 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
126 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-05 |
4 |
AB |
$8.02 |
$52,418 |
I/I |
6,540 |
22,791,378 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-05-22 |
4 |
AB |
$8.06 |
$40,558 |
I/I |
5,033 |
22,740,305 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-19 |
4 |
AB |
$8.17 |
$40,495 |
I/I |
4,957 |
22,860,013 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-18 |
4 |
AB |
$8.21 |
$55,061 |
I/I |
6,706 |
22,855,056 |
0 |
- |
|
MYOV |
Myovant Sciences Ltd. |
10% Owner |
|
2019-06-04 |
4 |
B |
$8.25 |
$19,999,997 |
I/I |
2,424,242 |
40,765,599 |
1.5 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-12 |
4 |
AB |
$8.30 |
$62,244 |
I/I |
7,500 |
22,827,298 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-10 |
4 |
AB |
$8.35 |
$62,594 |
I/I |
7,500 |
22,812,609 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-05-21 |
4 |
AB |
$8.52 |
$85,108 |
I/I |
9,995 |
22,735,272 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-17 |
4 |
AB |
$8.53 |
$55,825 |
I/I |
6,541 |
22,848,350 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-11 |
4 |
AB |
$8.58 |
$61,694 |
I/I |
7,189 |
22,819,798 |
0 |
- |
|
MDVN |
Medivation Inc |
Director |
|
2015-01-27 |
4 |
OE |
$9.39 |
$346,613 |
D/D |
36,000 |
67,500 |
0 |
- |
|
MDVN |
Medivation Inc |
Director |
|
2015-02-10 |
4 |
OE |
$9.39 |
$337,860 |
D/D |
36,000 |
67,500 |
0 |
- |
|
MDVN |
Medivation Inc |
Director |
|
2015-06-04 |
4 |
OE |
$9.39 |
$337,860 |
D/D |
36,000 |
67,500 |
0 |
- |
|
ADVM |
Adverum Biotechnologies, ... |
Director |
|
2021-03-24 |
4 |
B |
$9.92 |
$99,196 |
D/D |
10,000 |
88,182 |
2.39 |
% |
|
MDVN |
Medivation Inc |
Chief Business Officer and CFO |
|
2014-01-21 |
4 |
OE |
$10.59 |
$423,400 |
D/D |
40,000 |
70,830 |
0 |
- |
|
MDVN |
Medivation Inc |
Chief Business Officer and CFO |
|
2014-01-28 |
4 |
OE |
$10.59 |
$423,400 |
D/D |
40,000 |
70,830 |
0 |
- |
|
MDVN |
Medivation Inc |
Chief Business Officer and CFO |
|
2014-02-05 |
4 |
OE |
$10.59 |
$423,400 |
D/D |
40,000 |
70,830 |
0 |
- |
|
MDVN |
Medivation Inc |
Chief Business Officer and CFO |
|
2014-02-11 |
4 |
OE |
$10.59 |
$423,400 |
D/D |
40,000 |
70,830 |
0 |
- |
|
MDVN |
Medivation Inc |
Chief Business Officer and CFO |
|
2014-02-18 |
4 |
OE |
$10.59 |
$423,400 |
D/D |
40,000 |
70,830 |
0 |
- |
|
ADVM |
Adverum Biotechnologies, ... |
Director |
|
2021-01-15 |
4 |
B |
$11.52 |
$115,174 |
D/D |
10,000 |
78,182 |
2.39 |
% |
|
MDVN |
Medivation Inc |
Chief Business Officer and CFO |
|
2012-02-07 |
4 |
OE |
$11.76 |
$192,758 |
I/I |
16,391 |
80,807 |
0 |
- |
|
MDVN |
Medivation Inc |
Chief Business Officer and CFO |
|
2012-02-08 |
4 |
OE |
$11.76 |
$225,710 |
I/I |
19,193 |
57,093 |
0 |
- |
|
MDVN |
Medivation Inc |
Chief Business Officer and CFO |
|
2012-04-27 |
4 |
OE |
$11.76 |
$117,600 |
D/D |
10,000 |
31,511 |
0 |
- |
|
MDVN |
Medivation Inc |
Chief Business Officer and CFO |
|
2012-05-22 |
4 |
OE |
$11.76 |
$7,056 |
D/D |
600 |
22,111 |
0 |
- |
|
MDVN |
Medivation Inc |
Chief Business Officer and CFO |
|
2012-05-24 |
4 |
OE |
$11.76 |
$110,544 |
D/D |
9,400 |
30,911 |
0 |
- |
|
126 Records found
|
|
Page 3 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|